Prostate Cancer

What is Prostate Cancer?

Prostate cancer is a malignant tumor that develops in the prostate gland, a walnut-sized organ that surrounds the urethra and produces seminal fluid in men. It is the second most common cancer in men worldwide and primarily affects older adults, with most cases occurring after age 65. The disease ranges from slow-growing tumors that may never cause problems to aggressive cancers that can spread rapidly to other parts of the body. Early-stage prostate cancer often produces no symptoms, making regular screening important for men at risk.

Key statistics

Symptoms

Common symptoms include: difficulty urinating, weak urine flow, frequent urination especially at night, blood in urine or semen, pelvic discomfort, erectile dysfunction.

Early-stage symptoms: Many men with early prostate cancer experience no symptoms at all. When symptoms do occur, they often include difficulty starting urination, weak or interrupted urine flow, and increased frequency of urination, particularly at night. These symptoms can easily be mistaken for benign prostate enlargement, which is common in older men.

Advanced symptoms: As the cancer progresses, men may experience blood in urine or semen, painful urination, and erectile dysfunction. Pain in the hips, spine, chest, or pelvis may indicate the cancer has spread to bones. Advanced disease can also cause fatigue, unexplained weight loss, and swelling in the legs or feet.

Submit Your Paper

Causes and risk factors

The exact cause of prostate cancer remains unknown, but researchers have identified several risk factors. Age is the strongest risk factor, with risk increasing dramatically after age 50. African American men have nearly twice the risk of developing prostate cancer compared to men of other races and are more likely to develop aggressive forms of the disease.

Genetics play a significant role, with inherited mutations in genes such as BRCA1, BRCA2, and Lynch syndrome genes increasing risk. Men with a father or brother who had prostate cancer have double the risk of developing the disease. Geographic and dietary factors may also contribute, as prostate cancer rates are highest in North America and Northwestern Europe and lowest in Asia. High consumption of red meat and high-fat dairy products may increase risk, while diets rich in fruits and vegetables may be protective.

Prevention

While there is no guaranteed way to prevent prostate cancer, several evidence-based strategies may reduce risk. Maintaining a healthy diet rich in fruits, vegetables, and omega-3 fatty acids while limiting red meat and high-fat foods may be beneficial. Regular physical exercise and maintaining a healthy weight are associated with lower prostate cancer risk.

The U.S. Preventive Services Task Force recommends that men aged 55-69 discuss the benefits and risks of PSA screening with their healthcare provider. Men at higher risk, including African Americans and those with family history, should begin these discussions at age 45. Some studies suggest that medications like finasteride may reduce prostate cancer risk, but this should be discussed with a physician due to potential side effects.

Complications

Without treatment, prostate cancer can spread beyond the prostate capsule to nearby tissues, lymph nodes, and distant organs, particularly bones. Metastatic prostate cancer most commonly affects the spine, pelvis, and ribs, causing significant pain and potentially leading to fractures or spinal cord compression.

Advanced prostate cancer can cause urinary obstruction, requiring catheterization or surgical intervention. The cancer may also compress nerves, leading to weakness or paralysis. Treatment-related complications can include urinary incontinence, erectile dysfunction, and bowel problems following surgery or radiation therapy. Hormone therapy, while effective against cancer, can cause hot flashes, osteoporosis, muscle loss, and cardiovascular problems.

Diagnosis

Prostate cancer diagnosis typically begins with a prostate-specific antigen (PSA) blood test and digital rectal examination (DRE). Elevated PSA levels or abnormal DRE findings may prompt further testing, though PSA can be elevated due to benign conditions.

Advanced imaging studies include multiparametric MRI, which can identify suspicious areas within the prostate and help guide biopsy procedures. The gold standard for diagnosis is a transrectal or transperineal prostate biopsy, where tissue samples are examined under a microscope. Genetic testing for hereditary cancer syndromes may be recommended for men with family histories or early-onset disease.

Additional staging tests for confirmed cancer include CT scans, bone scans, and newer imaging techniques like PSMA PET scans to determine if the cancer has spread. The Gleason score system grades cancer aggressiveness based on tissue appearance, helping guide treatment decisions.

Treatment

Treatment options depend on cancer stage, grade, patient age, and overall health. For low-risk, early-stage cancer, active surveillance may be appropriate, involving regular monitoring without immediate treatment.

Surgical options include radical prostatectomy, which can be performed through open, laparoscopic, or robotic approaches. Radiation therapy options include external beam radiation and brachytherapy (radioactive seed implants).

For advanced or metastatic disease, hormone therapy forms the backbone of treatment. Medications include leuprolide, goserelin, and degarelix for androgen suppression. Newer agents like abiraterone, enzalutamide, and apalutamide provide additional hormone-blocking mechanisms.

Chemotherapy with docetaxel or cabazitaxel may be used for hormone-resistant disease. Immunotherapy with sipuleucel-T and targeted radiotherapy with radium-223 offer additional options for specific patient populations.

Prognosis

Prognosis for prostate cancer is generally excellent when detected early. The five-year survival rate for localized prostate cancer approaches 100%. Even when cancer has spread to nearby tissues and lymph nodes, the five-year survival rate remains around 100%. For metastatic disease, the five-year survival rate drops to approximately 30%, though many men live much longer with appropriate treatment.

Factors affecting prognosis include cancer stage and grade at diagnosis, PSA levels, patient age and overall health, and response to treatment. Many men diagnosed with prostate cancer will die of other causes, as the disease often progresses slowly, particularly in older patients.

Quality of life

Living with prostate cancer requires ongoing medical care and lifestyle adjustments. Men should maintain regular follow-up appointments and monitoring as recommended by their healthcare team. A balanced diet rich in fruits, vegetables, and whole grains while limiting processed foods may help overall health and potentially slow cancer progression.

Regular physical activity, adapted to individual capabilities, can help maintain strength, reduce fatigue, and improve mood. Pelvic floor exercises may help with urinary incontinence following treatment. Mental health support through counseling, support groups, or therapy can help cope with diagnosis-related anxiety and depression.

Sexual health may be affected by treatment, and men should discuss options with their healthcare providers, including medications, devices, or procedures to address erectile dysfunction. Open communication with partners about physical and emotional changes is important for maintaining relationships.

Pregnancy and fertility

Prostate cancer does not directly affect pregnancy outcomes, as it affects only men. However, treatment can significantly impact fertility. Surgery and radiation therapy may affect the ability to father children naturally, while hormone therapy can reduce sperm production and libido.

Men planning to father children should discuss sperm banking before beginning treatment. Some treatments may cause temporary or permanent infertility, making preservation of genetic material important for future family planning. Partners of men with hereditary forms of prostate cancer may benefit from genetic counseling to understand risks for future children.

Children

Prostate cancer is extremely rare in children and adolescents, with fewer than 100 cases reported in medical literature. When it does occur in young people, it is often associated with genetic syndromes or hormonal abnormalities.

Sons of men with prostate cancer have increased risk of developing the disease later in life and should discuss early screening with healthcare providers. Genetic counseling may be appropriate for families with multiple affected members or early-onset disease.

When to see a doctor

Men should seek immediate medical attention for severe pelvic pain, inability to urinate, or blood in urine accompanied by pain. Sudden onset of back pain, especially with weakness in the legs, may indicate spinal involvement and requires emergency evaluation.

Routine screening discussions should begin at age 50 for average-risk men, age 45 for high-risk men (African Americans or those with family history), and age 40 for men with multiple family members affected by prostate cancer. Any persistent urinary symptoms lasting more than a few weeks warrant medical evaluation.

Regional context

Prostate cancer incidence varies across the Caucasus region, with rates generally lower than those in Western countries but increasing with improved healthcare access and aging populations. Georgia has developed prostate cancer screening programs in major cities, while Armenia and Azerbaijan are expanding urological services.

GMJ welcomes contributions from regional researchers to build the evidence base for prostate cancer in the Caucasus, particularly regarding genetic factors, environmental influences, and treatment outcomes specific to these populations.

Research and clinical trials

Current research focuses on precision medicine approaches, using genetic profiling to guide treatment selection. Immunotherapy combinations, novel hormone therapies, and targeted radiotherapeutics are areas of active investigation. Artificial intelligence applications for imaging interpretation and treatment planning show promising results.

Recent breakthroughs include PARP inhibitors for men with DNA repair gene mutations and novel imaging agents for better cancer detection. Patients interested in clinical trials can search ClinicalTrials.gov for available studies in their area.

Frequently asked questions

Does having an enlarged prostate mean I have cancer?

No. Benign prostatic hyperplasia (BPH) is a common, non-cancerous condition that causes similar symptoms to prostate cancer. However, both conditions can occur simultaneously, so proper evaluation is important.

Should I get PSA testing?

PSA testing recommendations vary by age and risk factors. Men should discuss the benefits and limitations of PSA testing with their healthcare provider to make an informed decision based on their individual circumstances.

Will treatment affect my sex life?

Treatment can affect sexual function, but many men maintain satisfactory sexual relationships after treatment. Various options exist to address erectile dysfunction, and discussing concerns with healthcare providers is important.

Can I prevent prostate cancer through diet?

While no diet can guarantee prevention, eating plenty of fruits and vegetables while limiting red meat and high-fat foods may reduce risk. Maintaining a healthy weight and staying physically active are also beneficial.

Is prostate cancer hereditary?

Genetics play a role in about 10% of prostate cancers. Men with fathers or brothers who had prostate cancer have increased risk and should discuss earlier screening with their doctors.

Support and resources

• Prostate Cancer Foundation – www.pcf.org
• American Cancer Society – www.cancer.org
• Prostate Cancer UK – prostatecanceruk.org
• International Cancer Information Service Groups – www.iicig.org
• European Association of Urology – uroweb.org
• National Cancer Institute – www.cancer.gov

Related conditions

• Benign Prostatic Hyperplasia – Non-cancerous prostate enlargement causing similar urinary symptoms
• Prostatitis – Inflammation of the prostate gland that can cause pain and urinary symptoms
• Bladder Cancer – Another urological malignancy that can cause blood in urine and urinary symptoms
• Kidney Cancer – Genitourinary cancer that may present with similar symptoms
• Hereditary Breast and Ovarian Cancer Syndrome – Genetic condition that increases prostate cancer risk in men

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.